We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Arcus Biosciences (RCUS) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Arcus Biosciences (RCUS - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of RCUS and the rest of the Medical group's stocks.
Arcus Biosciences is a member of our Medical group, which includes 887 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. RCUS is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for RCUS's full-year earnings has moved 35.39% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, RCUS has moved about 125.35% on a year-to-date basis. In comparison, Medical companies have returned an average of -2.78%. As we can see, Arcus Biosciences is performing better than its sector in the calendar year.
To break things down more, RCUS belongs to the Medical - Biomedical and Genetics industry, a group that includes 381 individual companies and currently sits at #51 in the Zacks Industry Rank. Stocks in this group have gained about 10.81% so far this year, so RCUS is performing better this group in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track RCUS. The stock will be looking to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Arcus Biosciences (RCUS) Outpaced Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of Arcus Biosciences (RCUS - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of RCUS and the rest of the Medical group's stocks.
Arcus Biosciences is a member of our Medical group, which includes 887 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. RCUS is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for RCUS's full-year earnings has moved 35.39% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, RCUS has moved about 125.35% on a year-to-date basis. In comparison, Medical companies have returned an average of -2.78%. As we can see, Arcus Biosciences is performing better than its sector in the calendar year.
To break things down more, RCUS belongs to the Medical - Biomedical and Genetics industry, a group that includes 381 individual companies and currently sits at #51 in the Zacks Industry Rank. Stocks in this group have gained about 10.81% so far this year, so RCUS is performing better this group in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track RCUS. The stock will be looking to continue its solid performance.